

Leishman: Developing Evidence based clinical recommendations for the treatment of Cutaneous Leishmaniasis in Europe.

Johannes Blum¹, Diana Lockwood², & Pierre Buffet³ on behalf of the Leishman clinical group

1 Swiss Tropical & Public Health Institute, 4002 Basel, Switzerland

2. London School of Hygiene & Tropical Medicine, Keppel St, London WC1E 7HT, UK

9. UMR945 University Pierre & Marie Curie INSERM UPMC , Hôpital Pitié Salpêtrière, APHP, 75651 Paris Cedex 13, France

The Leishman consortium clinical group has recently set up a clinical and diagnostic data base so that patient details and parasite analysis can be collected by an agreed protocol and shared between laboratories for analyses. There is little information on the treatment of CL in travellers. We have developed evidence based recommendations for a species based treatment approach. A systematic literature review was done and evidence graded using the Oxford evidence (A-D) system. Although not all situations are covered by solid evidence, we have developed a set of recommendations for Old World (*L. major*/*L. tropica*, *L. infantum*, *L. aethiopica*) and New World (*L. panamensis*/*L. guyanensis*/*L. braziliensis*, *L. peruviana*/*L. mexicana*) cutaneous leishmaniasis . Consistent with recent WHO recommendations, a step-wise treatment approach favouring non toxic local or oral treatment is proposed whenever applicable and adapted to the localization, number and origin of lesions. We also consider the treatment of mucosal leishmaniasis Old World and New World and management of patients with special features such as children, pregnant women and patients receiving immuno-suppressive treatment. Developing these guidelines will promote harmonisation of treatment regimens in the Leishman-associated centres and Trop Net sites. We shall then compare outcomes using these guidelines and do selected multicenter prospective clinical trials. We have published a review on the risk of travellers developing MCL after CL infection. 1

1. Local or systemic treatment for New World Cutaneous Leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. Blum J , Lockwood DN , Visser L,et al *Int Health* 2012 4(3):153-63

Other group members : Leo Visser, Leiden , Gundel Harms, Berlin, Mark Bailey, Birmingham, Eric Caumes, Paris, Jan Clerinx, Antwerp, Pieter P.A.M. van Thiel, Amsterdam, Gloria Morizot, Paris, Christoph Hatz, Zurich.

For Clinical leishmaniasis